Compare Novavax Inc (NVAX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs TotalEnergies SE — how do they compare? Novavax Inc trades at $12.78 (market cap $1.82B), while TotalEnergies SE trades at $86.54 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 105.4× Novavax Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and TotalEnergies SE for 90 Days on average.
| NVAX | TTE | |
|---|---|---|
Market Cap | $1.82B | $191.82B |
Volume | 6,198,505 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $12.56 | $93.60 |
52-Week Low | $6.22 | $57.39 |
Typical Hold Time | 59 Days | 90 Days |
Enterprise Value | $1.39B | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
TotalEnergies (TTE) trades at $87.25, up 3.59% today, with a bearish technical signal but strong fundamentals including a low P/E of 10.77 and robust cash flow. Recent earnings beat expectations in Q1 and Q2 2026, while the company announced a $10 billion investment in Argentina and plans for dividend growth through 2030, signaling strategic expansion.
The outlook is positive with analyst consensus at Buy and a $95.33 price target, though risks include declining revenue trends and geopolitical exposure. Upside potential hinges on execution of growth initiatives and energy price stability, while investor sentiment remains supported by shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
